Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBunzl Regulatory News (BNZL)

Share Price Information for Bunzl (BNZL)

Share Price is delayed by 15 minutes
Get Live Data
2,534.00    70.00 (2.84%)
Bid:
2,532.00
Ask:
2,534.00
Spread: 2.00 (0.079%)
Market Cap: £8.14b
BNZL Live PriceLast checked at - London Stock Exchange

Intraday Bunzl Share Chart

Trading Statement

Today 07:00

RNS Number : 2843J
Bunzl PLC
23 June 2026
 

23 June 2026

 BUNZL PRE-CLOSE STATEMENT

2026 outlook upgraded; bolt-on acquisition completed in Australia

Bunzl plc, the specialist international distribution and services Group, is updating the market today prior to entering its closed period for the six months ending 30 June 2026.

Group revenue over the first half of 2026 is expected to grow by around 4% at constant exchange rates, with underlying revenue growth of around 3%. We expect growth to be supported by inflation across certain categories in the second quarter, with product-cost increases driven by geopolitical events, and we are also seeing encouraging volume growth. Volume growth is expected to be driven by North America, with good growth in our Distribution business. Our Distribution business continues to see operational progress as a result of actions taken, with encouraging volume growth across customers and supported by the additional benefit from new business wins that were achieved towards the end of last year. Over the first half, acquisitions, net of disposals, are expected to contribute growth of around 1% to the Group, and currency is expected to have a relatively neutral impact on revenue at actual exchange rates.

The Group expects good year-on-year growth in adjusted operating profit over the first half at constant exchange rates. Operating margin is expected to be up modestly year-on-year due to the net impact of inflation in the second quarter, much of which is expected to be temporary in nature, and the annualisation of Nisbets synergies.

While we remain mindful of continuing macroeconomic and geopolitical uncertainties, we are encouraged by our performance and upgrade our 2026 guidance. The Group now expects revenue growth at constant exchange rates to be driven by modest underlying revenue growth, supported by some inflation, alongside a small benefit from acquisitions. Our operating margin guidance is unchanged and we continue to expect it to be slightly down year-on-year.

In April, Bunzl completed the acquisition of Scientifix Group, an Australian distributor of critical products and services to the Life Sciences and Biotechnology sectors that will expand the category offering of our existing business. In the 12 months to June 2026, the business is expected to generate revenue of AUD 18 million (c.£9 million).

Commenting on today's announcement, Frank van Zanten, Chief Executive Officer of Bunzl, said:

"Bunzl is expecting to deliver an improved performance in the first half, with continued underlying growth and robust profitability, demonstrating the resilience and agility of our business model. Furthermore, I am pleased that our North America Distribution business has achieved the good operational progress we had expected, with the business' responsiveness, agility and high service levels largely restored. We continue to expect 2026 to be a foundation for future profit growth.

I am also delighted to welcome Scientifix into the Group, a company that is an excellent strategic fit with our existing healthcare business in Australia, and further enhances our exposure to this attractive value-added sector. Our acquisition pipeline remains active and we continue to expect 2026 to be an improved year for acquisitions. We continue to see significant opportunities to further consolidate our fragmented global markets, and remain confident in our ability to generate long-term compounding growth and value creation for all of our stakeholders."

Conference call

There will be a live analyst and investor conference call and Q&A session from 8.00am (BST) today, hosted by Richard Howes (Chief Financial Officer). A replay will be available later in the day.

Dial-in number: + 44 20 3936 2999 / Access code: 534897

Enquiries:

Bunzl plc (Tel: +44 (0)20 7725 5000)

Frank van Zanten, Chief Executive Officer

Richard Howes, Chief Financial Officer

Sunita Entwisle, Head of Investor Relations and Communications

Teneo (Tel: +44 (0)20 7353 4200)

Martin Robinson

Kate Somerville

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBRGDLXGDDGLD
Date   Source Headline
6th Jan 20234:07 pmRNSDirector/PDMR Shareholding
5th Jan 20235:36 pmRNSDirector/PDMR Shareholding
3rd Jan 202311:43 amRNSTotal Voting Rights
21st Dec 20227:00 amRNSTrading Statement
20th Dec 20227:00 amRNSAcquisition
14th Dec 20228:00 amRNSAdditional Listing
8th Dec 202212:56 pmRNSHolding(s) in Company
5th Dec 20229:45 amRNSDirector/PDMR Shareholding
1st Dec 20222:34 pmRNSTotal Voting Rights
29th Nov 20223:21 pmRNSDirector/PDMR Shareholding
11th Nov 20229:00 amRNSPublication of Admission Particulars
4th Nov 202212:08 pmRNSDirector/PDMR Shareholding
2nd Nov 20224:20 pmRNSDirector/PDMR Shareholding
1st Nov 20223:00 pmRNSTotal Voting Rights
1st Nov 202210:00 amRNSBlock listing Interim Review
20th Oct 20227:00 amRNSTrading Statement
11th Oct 20227:00 amRNSInvestor event
7th Oct 20224:11 pmRNSDirector/PDMR Shareholding
4th Oct 20224:54 pmRNSDirector/PDMR Shareholding
3rd Oct 20223:13 pmRNSTotal Voting Rights
20th Sep 20227:00 amRNSHolding(s) in Company
7th Sep 202210:59 amRNSDirector/PDMR Shareholding
1st Sep 202211:08 amRNSTotal Voting Rights
31st Aug 20221:46 pmRNSDirector/PDMR Shareholding
30th Aug 202210:00 amRNSDividend Declaration
30th Aug 20227:00 amRNSHalf-year Report
4th Aug 20229:19 amRNSDirector/PDMR Shareholding
2nd Aug 20227:00 amRNSAcquisition
1st Aug 20223:07 pmRNSTotal Voting Rights
1st Aug 202210:00 amRNSDirector Declaration
29th Jul 20227:00 amRNSAppointment of Joint Corporate Broker
19th Jul 20227:00 amRNSDirectorate Change
12th Jul 202210:32 amRNSDirector/PDMR Shareholding
6th Jul 20225:12 pmRNSDirector/PDMR Shareholding
1st Jul 20222:18 pmRNSTotal Voting Rights
30th Jun 20227:00 amRNSTrading Statement
14th Jun 20227:00 amRNSAcquisition
8th Jun 202212:44 pmRNSDirector/PDMR Shareholding
1st Jun 202210:42 amRNSTotal Voting Rights
11th May 20228:00 amRNSAdditional Listing
5th May 202211:00 amRNSDirector/PDMR Shareholding
3rd May 202211:00 amRNSTotal Voting Rights
3rd May 202210:00 amRNSBlock listing Interim Review
28th Apr 20228:00 amRNSAdditional Listing
20th Apr 20225:17 pmRNSResult of AGM
20th Apr 20227:00 amRNSTrading Statement
19th Apr 20224:59 pmRNSDirector/PDMR Shareholding
8th Apr 20225:37 pmRNSDirector/PDMR Shareholding
8th Apr 20225:36 pmRNSDirector/PDMR Shareholding
7th Apr 20222:45 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.